Andrew H Wei
Overview
Explore the profile of Andrew H Wei including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
150
Citations
10980
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gisriel S, Aakash F, Bennett J, Hasserjian R, Loghavi S, DeZern A, et al.
Arch Pathol Lab Med
. 2025 Mar;
PMID: 40059041
Context.—: Standardized bone marrow reporting specifically for myelodysplastic syndromes/neoplasms (MDS) is currently lacking in the literature and much needed in practice. Objective.—: To propose a standardized approach to MDS evaluation...
2.
Li K, Yap Y, Moujalled D, Sumardy F, Khakham Y, Georgiou A, et al.
Sci Adv
. 2025 Mar;
11(10):eadr8146.
PMID: 40043112
Defective apoptosis mediated by B cell lymphoma 2 antagonist/killer (BAK) or B cell lymphoma 2-associated X protein (BAX) underlies various pathologies including autoimmune and degenerative conditions. On mitochondria, voltage-dependent anion...
3.
Goulart H, Wei A, Kadia T
Am J Hematol
. 2025 Feb;
100 Suppl 2:38-49.
PMID: 39960005
Over the last decade, there have been significant advancements in the treatment for patients with acute myeloid leukemia (AML) including the addition of novel, targeted agents to intensive or nonintensive...
4.
Iland H, Reynolds J, Boddy A, Schultz H, Khoo L, Fleming S, et al.
Blood Adv
. 2025 Jan;
PMID: 39874494
The prognosis for patients with acute promyelocytic leukemia (APL) has improved dramatically since the introduction of all-trans retinoic acid (ATRA) and intravenous arsenic trioxide (ATO). However, ATO administration requires daily...
5.
Chua C, Loo S, Fong C, Ting S, Tiong I, Fleming S, et al.
Blood Adv
. 2025 Jan;
PMID: 39825857
Venetoclax plus azacitidine represents a key advance for older, unfit patients with acute myeloid leukemia (AML). The chemotherapy and venetoclax in elderly AML trial (CAVEAT) was first to combine venetoclax...
6.
Peng H, Jabbari J, Tian L, Wang C, You Y, Chua C, et al.
Genome Res
. 2025 Jan;
PMID: 39794120
Single-cell long-read sequencing has transformed our understanding of isoform usage and the mutation heterogeneity between cells. Despite unbiased in-depth analysis, the low sequencing throughput often results in insufficient read coverage,...
7.
Levis M, Hamadani M, Logan B, Jones R, Singh A, Litzow M, et al.
Blood
. 2025 Jan;
PMID: 39775763
BMT CTN 1506 ("MORPHO"; NCT02997202) was a randomized phase 3 study of gilteritinib compared to placebo as maintenance therapy after hematopoietic stem cell transplantation (HCT) for patients with FLT3-ITD-mutated acute...
8.
Atkin-Smith G, Santavanond J, Light A, Rimes J, Samson A, Er J, et al.
Nat Commun
. 2024 Oct;
15(1):8802.
PMID: 39438460
Endothelial cells are integral components of all vasculature within complex organisms. As they line the blood vessel wall, endothelial cells are constantly exposed to a variety of molecular factors and...
9.
Komrokji R, Lanino L, Ball S, Bewersdorf J, Marchetti M, Maggioni G, et al.
Lancet Haematol
. 2024 Oct;
11(11):e862-e872.
PMID: 39393368
The WHO and International Consensus Classification 2022 classifications of myelodysplastic syndromes enhance diagnostic precision and refine decision-making processes in these diseases. However, some discrepancies still exist and potentially cause inconsistency...
10.
Brown F, Wang X, Birkinshaw R, Chua C, Morley T, Kasapgil S, et al.
Blood Adv
. 2024 Oct;
9(1):127-131.
PMID: 39374584
No abstract available.